Showing results (41-50 of 453) with videos related to
Sort By:
Pageof 46
Nature Reviews. Clinical Oncology|March 7, 2018
Targeting the PI3K pathway in cancer: are we making headway?Filip Janku, Timothy A Yap, Funda Meric-BernstamClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2024
PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLCNatalie I Vokes, Xiuning Le, Timothy A YapEuropean Journal of Cancer (Oxford, England : 1990)|November 21, 2016
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancerTimothy A Yap, Aislinn Macklin-Doherty, Sanjay PopatJournal of Hematology & Oncology|October 4, 2014
Strategies for modern biomarker and drug development in oncologyAlan D Smith, Desam Roda, Timothy A YapCancers|April 3, 2021
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular PlasticitySarah Christine Elisabeth Wright, Natali Vasilevski, Violeta Serra, et al.Oncotarget|November 12, 2016
Unveiling changes in the landscape of patient populations in cancer early drug developmentCinta Hierro, Analía Azaro, Guillem Argilés, et al.JCO Precision Oncology|February 2, 2022
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced CancersBenjamin Garmezy, Jinesh Gheeya, Heather Y Lin, et al.Investigational New Drugs|September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory studyRony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.Current Problems in Cancer|April 19, 2017
Circulating tumor DNA-From bench to bedsideJoline S J Lim, Filip Janku, Timothy A YapExpert Opinion on Pharmacotherapy|July 26, 2021
Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancerEvthokia A Hobbs, Jennifer K Litton, Timothy A YapPageof 46